NCT05143229: Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer

Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with unstable untreated symptomatic brain metastases – see trial for details; Patients who have NOT received at least one line of chemotherapy, one line of hormonal therapy (where appropriate), and/or one line of anti-PD-1 and/or anti-PD-L1 therapy for those who are eligible (e.g. Tecentriq/atezolizumab, Keytruda/pembrolizumab) in either the advanced or neoadjuvant setting; Patients who have previously been treated with Trodelvy/sacituzumab govitecan or Piqray/alpelisib; Patients who have received previous treatment with a PI3K inhibitor or AKT inhibitor

Comments are closed.

Up ↑